B. Riley Has Bullish Estimate for Electromed Q2 Earnings

Electromed, Inc. (NYSE:ELMD - Free Report) - Research analysts at B. Riley lifted their Q2 2026 earnings per share (EPS) estimates for Electromed in a report issued on Thursday, November 13th. B. Riley analyst A. Schock now anticipates that the company will post earnings per share of $0.28 for the quarter, up from their previous forecast of $0.25. B. Riley also issued estimates for Electromed's Q3 2026 earnings at $0.26 EPS, FY2026 earnings at $1.09 EPS, Q1 2027 earnings at $0.31 EPS, Q2 2027 earnings at $0.34 EPS, Q3 2027 earnings at $0.32 EPS, Q4 2027 earnings at $0.38 EPS and FY2027 earnings at $1.36 EPS.

Other research analysts have also issued research reports about the stock. Lake Street Capital initiated coverage on shares of Electromed in a research note on Wednesday, August 27th. They issued a "buy" rating and a $36.00 price objective for the company. Roth Capital reissued a "buy" rating and issued a $36.00 price target (up previously from $35.00) on shares of Electromed in a research report on Thursday. Loop Capital set a $36.00 price target on shares of Electromed in a research note on Wednesday, August 27th. Finally, Zacks Research lowered Electromed from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Electromed has an average rating of "Buy" and an average price target of $36.50.

Get Our Latest Stock Analysis on ELMD

Electromed Trading Down 5.0%

ELMD traded down $1.31 during mid-day trading on Friday, hitting $25.04. 7,093 shares of the stock were exchanged, compared to its average volume of 77,355. The firm's fifty day moving average is $24.60 and its two-hundred day moving average is $21.98. Electromed has a 1-year low of $17.73 and a 1-year high of $35.56. The company has a market cap of $209.74 million, a PE ratio of 33.39 and a beta of 0.40.

Hedge Funds Weigh In On Electromed

Several hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its holdings in Electromed by 0.4% during the third quarter. Dimensional Fund Advisors LP now owns 190,103 shares of the company's stock worth $4,667,000 after purchasing an additional 696 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Electromed by 3.1% in the 2nd quarter. American Century Companies Inc. now owns 32,031 shares of the company's stock valued at $704,000 after buying an additional 969 shares in the last quarter. Spire Wealth Management grew its position in shares of Electromed by 22.7% in the 2nd quarter. Spire Wealth Management now owns 5,405 shares of the company's stock valued at $119,000 after buying an additional 1,000 shares during the last quarter. Raymond James Financial Inc. raised its stake in Electromed by 1.8% during the 2nd quarter. Raymond James Financial Inc. now owns 58,331 shares of the company's stock worth $1,283,000 after acquiring an additional 1,053 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Electromed in the second quarter valued at $32,000. 40.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Electromed

In related news, Director Andrew Summers sold 3,153 shares of the business's stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $24.42, for a total transaction of $76,996.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.50% of the company's stock.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.

Read More

• Five stocks we like better than Electromed
• The Basics of Support and Resistance
• CRWD Stock Hits Key Inflection Point Ahead of Earnings
• What Are Dividend Challengers?
• Rigetti’s Q3 Miss Reveals Quantum Funding and Timing Pressures
• 3 Fintech Stocks With Good 2021 Prospects
• Monolithic Power Surges in 2025—Time to Buy or Hold?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Electromed Right Now?

Before you consider Electromed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Electromed wasn't on the list.

While Electromed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here